Investors
Corporate Profile
Genomic Health (Nasdaq: GHDX) is focused on the development and commercialization of
genomic-based clinical diagnostic tests for cancer that allow physicians and patients
to make individualized treatment decisions. In early 2004, we launched our first test
under the brand name Oncotype DX® for early stage breast cancer patients. We believe
that Oncotype DX is the first genomic test that has clinical evidence supporting its
ability to predict the likelihood of cancer recurrence, the likelihood of patient
survival within 10 years of diagnosis and the likelihood of chemotherapy benefit.
Recent Press Releases
May 8, 2008
Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference
May 6, 2008
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
 All Press Releases
Webcasts
All Events and Webcasts
Forward Looking Statements
This website contains forward-looking statements based on certain assumptions and
expectations. For this purpose, any statements contained in this website that are not
statements of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and
similar expressions are intended to identify forward-looking statements. These
risks and uncertainties include, but are not limited to, risks and uncertainties
relating to our expectation that, for the foreseeable future, substantially all
of our revenues will be derived from Oncotype DX; our dependence on collaborative
relationships; the regulation of Oncotype DX by the FDA; our ability, and
expectations as to the amount of time it will take, to achieve successful
reimbursement from third-party payors and government insurance programs; and the
attributes of our products; the outcome and success of clinical trials; and future
financial results. For a discussion of other factors that may cause Genomic
Health's actual results to differ from those projected, expressed or implied
by the forward looking statements, please refer to the Company's Registration
Statement on Form S-1 as well as other subsequent filings with the Securities
and Exchange Commission. We do not undertake, and specifically disclaim any
obligation, to revise any forward looking statements to reflect the occurrence
of anticipated or unanticipated events or circumstances after the date of such
statements.
|
